Exome Asset Management LLC In its 13F for Q1 2026 (holdings as of March 31, 2026, filed May 15, 2026), Exome Asset Management LLC reported 45 stock positions worth $169.9 million . Its top holding was Praxis Precision Medicines I (PRAX) at 8.6% of the portfolio, followed by Cogent Biosciences (COGT, 6.3% ) and Enliven Therapeutics (ELVN, 5.1% ). Compared with Q4 2025, it opened 14 new positions, sold out of 22, added to 4 and reduced 23. The biggest buy was a new position in Insmed (INSM) and the biggest sale an exit from Wave Life Sciences (WVE).
Location NEW YORK, NY
CIK 0002011932
Portfolio Value $169.9M (Q1 2026) Holdings 45 stocks · $169.9M Holdings quarter Q2 2026 Q1 2026 Q4 2025 Q3 2025 Q2 2025 Q1 2025 Q4 2024 Q3 2024 Q2 2024 Q1 2024
Stock % Of Portfolio ▼ Shares Held Total Value Change vs Q4 2025 PRAX Praxis Precision Medicines I 45,469 $14.6M Reduce -21.8% COGT Cogent Biosciences Inc. 278,533 $10.7M Reduce -8.8% ELVN Enliven Therapeutics Inc. 220,091 $8.6M Reduce -1.0% IONS Ionis Pharmaceuticals Inc. 110,064 $8.3M Reduce -5.5% GH Guardant Health Inc. 82,736 $7.6M Reduce -15.7% CYTK Cytokinetics Inc. 103,718 $6.8M Reduce -16.9% LLY Eli Lilly & Co. 7,012 $6.4M Reduce -10.7% ALMS Alumis Inc. 279,176 $6.2M Reduce -4.5% BBIO Bridgebio Pharma Inc. 67,492 $5.0M Reduce -16.4% VERA Vera Therapeutics Inc. 114,991 $4.6M Reduce -7.6% INSM Insmed Inc. 26,651 $4.4M New ELV Elevance Health Inc. 14,677 $4.3M Reduce -14.6% AGIO Agios Pharmaceuticals Inc. 125,060 $4.2M Reduce -8.7% UTHR United Therapeutics Corp. 7,053 $4.2M Reduce -8.2% MLTX Moonlake Immunotherapeutics 215,376 $4.0M New NTRA Natera Inc. 18,650 $3.7M No change RYTM Rhythm Pharmaceuticals Inc. 40,581 $3.5M New UNH Unitedhealth Group Inc. 12,862 $3.5M Add +120.4% APLS Apellis Pharmaceuticals Inc. 85,517 $3.4M Reduce -37.0% VSTM Verastem Inc. 636,700 $3.4M Add +58.5% TXG 10X Genomics Inc. Class A 154,194 $3.3M Reduce -5.8% BSX Boston Scientific Corp. 48,347 $3.0M New ALKS Alkermes PLC 84,103 $3.0M New GLUE Monte Rosa Therapeutics Inc. 179,484 $3.0M New ISRG Intuitive Surgical Inc. 6,358 $2.9M No change ADAG Adagene Inc.-ADR 736,845 $2.9M Reduce -30.5% ARWR Arrowhead Pharmaceuticals Inc. 45,721 $2.9M Reduce -8.1% CBIO Crescent Biopharma Inc. 153,191 $2.8M New RLAY Relay Therapeutics Inc. 278,302 $2.8M New MAZE Maze Therapeutics Inc. 88,510 $2.6M New CTMX Cytomx Therapeutics Inc. 521,468 $2.5M Reduce -30.0% AVTX Avalo Therapeutics Inc. 159,341 $2.4M New GKOS Glaukos Corp. 20,874 $2.2M Reduce -33.7% CRBP Corbus Pharmaceuticals Holdi 234,136 $2.2M Add +67.8% PEN Penumbra Inc. 6,300 $2.1M Reduce -30.0% SLNO Soleno Therapeutics Inc. 61,673 $2.1M New LQDA Liquidia Corp. 45,796 $1.7M Reduce -49.8% ZBIO Zenas Biopharma Inc. 80,730 $1.6M New NBP Novabridge Biosciences 576,960 $1.4M Add +15.5% FDMT 4D Molecular Therapeutics Inc. 130,564 $1.2M New NXTC Nextcure Inc. 115,500 $1.2M Reduce -30.0% PALI Palisade Bio Inc. 600,000 $1.1M Reduce -20.9% ESTA Establishment Labs Holdings 13,100 $744K No change LPCN Lipocine Inc. 60,861 $486K New ABUS Arbutus Biopharma Corp. 75,484 $340K No change
Options reported separately and not counted above: XBI puts ($7.7M), CYTOKINETICS INC puts ($4.0M), BEIGENE LTD calls ($3.0M), ALUMIS INC puts ($2.3M), LIQUIDIA CORPORATION puts ($1.5M), CENTESSA PHARMACEUTICALS PLC puts ($1.4M), IDEAYA BIOSCIENCES INC calls ($1.3M), IDEAYA BIOSCIENCES INC puts ($1.3M), TRAVERE THERAPEUTICS INC puts ($594K), WAVE LIFE SCIENCES LTD puts ($218K), COMPASS THERAPEUTICS INC calls ($133K).
Portfolio Sells Q4 2025 → Q1 2026 Portfolio Sells quarter Q2 2026 Q1 2026 Q4 2025 Q3 2025 Q2 2025 Q1 2025 Q4 2024 Q3 2024 Q2 2024 Q1 2024
Stock Change vs Q4 2025 % Of Portfolio Change To Portfolio ▲ WVE Wave Life Sciences Ltd. Sold out 0.00% −3.54 AZN Astrazeneca PLC-Spons ADR Sold out 0.00% −2.60 JAZZ Jazz Pharmaceuticals PLC Sold out 0.00% −2.23 IMVT Immunovant Inc. Sold out 0.00% −1.99 UHS Universal Health Services-B Sold out 0.00% −1.90 IRON Disc Medicine Inc. Sold out 0.00% −1.83 CELC Celcuity Inc. Sold out 0.00% −1.69 TVTX Travere Therapeutics Inc. Sold out 0.00% −1.68 DXCM Dexcom Inc. Sold out 0.00% −1.64 IMCR Immunocore Holdings PLC-ADR Sold out 0.00% −1.32 EWTX Edgewise Therapeutics Inc. Sold out 0.00% −1.23 BLTE Belite Bio Inc. - ADR Sold out 0.00% −1.13 WAY Waystar Holding Corp. Sold out 0.00% −1.12 IRWD Ironwood Pharmaceuticals Inc. Sold out 0.00% −1.08 KPTI Karyopharm Therapeutics Inc. Sold out 0.00% −1.07 UPB Upstream Bio Inc. Sold out 0.00% −0.87 GOSS Gossamer Bio Inc. Sold out 0.00% −0.69 IKT Inhibikase Therapeutics Inc. Sold out 0.00% −0.61 IQV Iqvia Holdings Inc. Sold out 0.00% −0.60 THC Tenet Healthcare Corp. Sold out 0.00% −0.60 LQDA Liquidia Corp. Reduce -49.8% 1.02% −0.54 FULC Fulcrum Therapeutics Inc. Sold out 0.00% −0.51 GH Guardant Health Inc. Reduce -15.7% 4.50% −0.46 ELV Elevance Health Inc. Reduce -14.6% 2.53% −0.45 NXTC Nextcure Inc. Reduce -30.0% 0.71% −0.44 GKOS Glaukos Corp. Reduce -33.7% 1.32% −0.43 VERA Vera Therapeutics Inc. Reduce -7.6% 2.72% −0.39 LLY Eli Lilly & Co. Reduce -10.7% 3.79% −0.37 PALI Palisade Bio Inc. Reduce -20.9% 0.62% −0.26 RAPT Rapt Therapeutics Inc. Sold out 0.00% −0.24 PEN Penumbra Inc. Reduce -30.0% 1.22% −0.17 CTMX Cytomx Therapeutics Inc. Reduce -30.0% 1.44% −0.13 BBIO Bridgebio Pharma Inc. Reduce -16.4% 2.95% −0.10 ARWR Arrowhead Pharmaceuticals Inc. Reduce -8.1% 1.69% +0.05 CYTK Cytokinetics Inc. Reduce -16.9% 4.02% +0.11 PRAX Praxis Precision Medicines I Reduce -21.8% 8.62% +0.16 IONS Ionis Pharmaceuticals Inc. Reduce -5.5% 4.86% +0.31 APLS Apellis Pharmaceuticals Inc. Reduce -37.0% 2.02% +0.34 TXG 10X Genomics Inc. Class A Reduce -5.8% 1.93% +0.61 UTHR United Therapeutics Corp. Reduce -8.2% 2.46% +0.61 AGIO Agios Pharmaceuticals Inc. Reduce -8.7% 2.49% +0.65 ADAG Adagene Inc.-ADR Reduce -30.5% 1.70% +0.71 COGT Cogent Biosciences Inc. Reduce -8.8% 6.31% +0.95 ALMS Alumis Inc. Reduce -4.5% 3.62% +2.21 ELVN Enliven Therapeutics Inc. Reduce -1.0% 5.08% +3.39
Portfolio Buys Q4 2025 → Q1 2026 Portfolio Buys quarter Q2 2026 Q1 2026 Q4 2025 Q3 2025 Q2 2025 Q1 2025 Q4 2024 Q3 2024 Q2 2024 Q1 2024
Stock Change vs Q4 2025 % Of Portfolio Change To Portfolio ▼ INSM Insmed Inc. New 2.56% +2.56 MLTX Moonlake Immunotherapeutics New 2.36% +2.36 RYTM Rhythm Pharmaceuticals Inc. New 2.08% +2.08 BSX Boston Scientific Corp. New 1.79% +1.79 ALKS Alkermes PLC New 1.75% +1.75 GLUE Monte Rosa Therapeutics Inc. New 1.74% +1.74 CBIO Crescent Biopharma Inc. New 1.66% +1.66 RLAY Relay Therapeutics Inc. New 1.63% +1.63 MAZE Maze Therapeutics Inc. New 1.55% +1.55 AVTX Avalo Therapeutics Inc. New 1.40% +1.40 SLNO Soleno Therapeutics Inc. New 1.22% +1.22 UNH Unitedhealth Group Inc. Add +120.4% 2.05% +1.10 ZBIO Zenas Biopharma Inc. New 0.93% +0.93 CRBP Corbus Pharmaceuticals Holdi Add +67.8% 1.29% +0.73 FDMT 4D Molecular Therapeutics Inc. New 0.72% +0.72 VSTM Verastem Inc. Add +58.5% 1.99% +0.45 LPCN Lipocine Inc. New 0.29% +0.29 NBP Novabridge Biosciences Add +15.5% 0.84% −0.15
Options Activity Q4 2025 → Q1 2026 Security Type Change vs Q4 2025 Underlying Shares Value ▼ XBI SS SPDR S&P Biotech ETF put New 60,000 $7.7M CYTOKINETICS INC put New 60,000 $4.0M BEIGENE LTD call New 10,000 $3.0M ALUMIS INC put Add +97.4% 105,000 $2.3M LIQUIDIA CORPORATION put New 40,000 $1.5M CENTESSA PHARMACEUTICALS PLC put New 34,700 $1.4M IDEAYA BIOSCIENCES INC call New 40,000 $1.3M IDEAYA BIOSCIENCES INC put New 40,000 $1.3M DISC MEDICINE INC put Sold out 16,000 $1.3Mbefore exit ULTRAGENYX PHARMACEUTICAL IN call Sold out 35,200 $810Kbefore exit TRAVERE THERAPEUTICS INC put Reduce -73.2% 20,000 $594K ALDEYRA THERAPEUTICS INC call Sold out 100,000 $518Kbefore exit PRECIGEN INC put Sold out 100,000 $418Kbefore exit SOLENO THERAPEUTICS INC put Sold out 7,100 $328Kbefore exit WAVE LIFE SCIENCES LTD put New 30,000 $218K COMPASS THERAPEUTICS INC call New 25,100 $133K
Calls and puts are listed by the shares they cover; their value is not part of the stock holdings above.
All Filings Quarter Positions 13F Reported Value Top Holdings Q2 2026 52 $162.1M GH, PRAX, TGTX, COGT, IONS Q1 2026 45 $169.9M PRAX, COGT, ELVN, IONS, GH Q4 2025 53 $202.4M PRAX, COGT, GH, IONS, LLY Q3 2025 54 $151.4M IONS, CYTK, BBIO, COGT, GH Q2 2025 Amended 55 $121.3M ISHARES TR, BBIO, GH, GERN, IONS Q1 2025 Amended 49 $111.6M BBIO, GH, GERN, AZN, CYTK Q4 2024 58 $132.9M BBIO, LLY, GERN, HUM, GH Q3 2024 Amended 59 $147.9M LLY, ASND, BBIO, GPCR, TGTX Q2 2024 Amended 52 $112.3M LLY, SRPT, ONC, TGTX, CI Q1 2024 53 $116.8M LLY, RDY, ONC, CI, ALPN